Want to join the conversation?
$AMGN's immunotherapy blockbuster Enbrel, delivered 30% growth in 3Q15 due to net selling price. Sensiper, a thyroid drug, grew 29%, driven by inventory, net selling price and unit growth in US and Europe. Prolia, a bone-strengthening drug, grew 25%. XGEVA, a drug for treating Giant Cell Tumor Of Bone, grew 19%.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?